Today, biosimilars are available for patients with a wide range of complex debilitating illnesses including chronic skin and bowel diseases (like psoriasis, irritable bowel syndrome, Crohn's disease and ulcerative colitis), diabetes, arthritis and cancer.1 Looking ahead to 2029, around 120 biologic medicines will lose their exclusivity.2 This opens the door for more biosimilars to benefit more patients living with different conditions3, provide physicians with a choice of therapies4, and give healthcare systems a way either to save money or divert that money to solve other pressing healthcare problems.5 However, if we are to realize all the benefits of biosimilars, action is needed to unlock their full potential.

Siluette of a woman

Biosimilars provide value for all stakeholders​

Siluette of elderly woman

Benefits to Patients

Biosimilars are an important tool to increase patient access to potentially life-changing medicines.6

Siluette of young business woman

Benefits to Payers

Biosimilars introduce competition, increasing affordability of biologics which delivers savings for healthcare systems8, helping to liberate resources that can be used to improve care and fund next-generation medicines.

Siluette from a doctor

Benefits to HCPs

Introduction of biosimilars drives competition, resulting in increased treatment options and value-added services to support patient care and the healthcare community.9



Biosimilars introduce competition, which leads to innovation such as enhancements of existing medicines and development of new treatments.7


Cumulative worldwide savings due to the availability of biosimilars is estimated to reach USD 215 billion between 2021 and 2026.8

Increased choice

Between 2021 and 2029, more than 120 biologic medicines will lose exclusivity - twice the number of biologics that have come off patent over the past decade.10

Explore how biosimilars have made a real impact in countries across the globe, demonstrating value for a range of stakeholders.

Following the entry of biosimilars into the market, and the subsequent reduction in the cost of treatment, in June 2021 the National Institute of Health and Care Excellence (NICE) issued revised guidelines and recommended the use of biologic therapies to a broader range of patients living with RA. The additional group included people living with moderate RA. Around 25,000 extra people with moderate RA who haven’t responded to conventional therapies are expected to benefit from these recommendations and access helpful treatment earlier in their treatment pathway.

Reference: Institute of Management Services. Delivering on the Promise of Biosimilar Medicines: The Role of Functioning Competitive Markets [online]. Available from:… Accessed July 2022 

Map from United Kingdom


The funding of a biosimilar brand and approval for its use by Medsafe (the New Zealand Medicines and Medical Devices Safety Authority) is enabling more individuals with cancers and inflammatory conditions to be treated each year and freeing up a limited budget to fund other medicines.

Reference:… Accessed November 2022

Map of New Zealand


An estimated 1.2 million US patients could gain access to biologics by 2025 as a result of increasing biosimilar availability. 
Reference: The Biosimilars Council. Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines. Available at:…

Map of United States (US)


Biosimilars give more people the opportunity to access biologic therapies. For example, after the introduction of biosimilars in Germany, the number of daily therapy doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) while costs fell by 11%. 

Reference: Zusammenfassung_MundiCare_Biosimilarstudie_Maerz-2021.pdf ( Accessed November 2022 

Map of Germany


In a hospital, patients with inflammatory bowel disease were switched to a biosimilar, which generated savings that were reinvested into the health system to streamline procedures and increase staff support.  As a result, patients experienced shorter wait times, improved pre-delivery procedures and a more efficient care pathway. 

Reference: ESNO. Switch Management between similar biological medicines. Available from…. Accessed November 2022

Map of Belgium


Before the launch of biosimilars, a supportive care for cancer could only be administered to patients after the consent of three physicians. Because of the reduction of the treatment costs due to biosimilar competition, the authorities relaxed the restrictions on prescribing, requiring consent from only one physician. This resulted in a 500% increased use of the treatment. 

Reference: ESNO. Switch Management between similar biological medicines. Available from…. Accessed November 2022

Map of Sweden


Patient access to biosimilar anti-TNF treatments has expanded by 15% in 2020.

Reference: IQVIA Spotlight on Biosimilars in Europe 2021 (Spotlight on Biosimilars - IQVIA) Accessed November 2022

Map of Denmark


Biologics uptake has historically been low, partly due to cost. However, these countries have seen significant uptake of biologic medicines once biosimilar versions have become available.

Reference: Institute of Management Services. Delivering on the Promise of Biosimilar Medicines: The Role of Functioning Competitive Markets [online]. Available from:… Accessed November 2022 

Map of Eastern Europe


Proportion of Rheumatoid Arthritis patients starting biologics treatment has increased from 10% (June 2017) to 80% (June 2021), due to strong improvement of treatment initiation mainly driven by biosimilar gain-sharing measures.

Reference:… p297 Accessed July 2022

Map of France


In Italy biosimilar adoption increased by 26.9% more in 2021 than 2020, making up 43% of the total reference market. This was also due to national and regional guidelines promoting the value of biosimilars to increase access to biologic treatments for those eligible for this kind of therapy.

Reference: Egualia report 3090.html ( Accessed November 2022 

Map of Italy


In Brazil in 2013, the National Therapeutic Guidelines for Psoriasis​ didn’t recommend any biologic drug for the treatment of psoriasis (all anti-TNFs were approved for this indication at the time)​. By 2020, four biosimilar treatment options were recommended following approval.​

Reference: Ministério da Saúde, Brasil. Protocolo Clínico e Diretrizes Terapêuticas – Psoríase (2013)​
Ministério da Saúde, Brasil. Protocolo Clínico e Diretrizes Terapêuticas – Psoríase (2020)

Map of Brazil


By 2024, savings for the Spanish Health Care System attributed to biosimilar implementation since 2007 are expected to reach a cumulative total of €12bn.

Reference: IQVIA Spain hospital data from 2007 to 2021; Tendering data; IQVIA analysis.​

Map of Spain


Biosimilars’ Benefits for Patients

There are many real-life examples across the world demonstrating how biosimilars bring benefits to patients.

Learn more


To learn more about the value of biosimilars, you can visit Act4Biosimilars. Act4Biosimilars is a global initiative founded and supported by Sandoz aimed at increasing patient access to biologics medicines by facilitating greater approvability, accessibility, acceptability and affordability of biosimilars. With a mission to increase the global adoption of biosimilars by at least 30% in 30+ countries by 2030, Act4Biosimilars is led by a multidisciplinary stakeholder group of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world.1

Learn more
  1. Medicines for Europe. Available at:…. [Accessed October 2022]
  2. GI Society. Biosimilars. Available at:…. [Accessed October 2022]
  3. Weise M, et al. Biosimilars: what clinicians should know. Blood 2012; 120:5111-7.
  4. Kay J. A ‘Wind of change’ to biosimilars: the NOR-SWITCH trial and its extension. J Intern Med. 2019; 285:693-5.
  5. FDA. Patient Materials. Available at: Accessed October 2022
  6. IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. 2016. Available from… [Accessed September 2022]
  7. Vulto AG, et al. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther. 2020 Oct; 108(4): 734-755 
  8. IQVIA. The Global Use of Medicines 2022. Available from:… [Accessed September 2022]
  9. Winegarden, W. Falling Prices: Biosimilar competition has saved billions of dollars, but policy changes can incentivize billions more. Pacific Research Institute, 2022.​
  10. IQVIA Institute for Human Data Science. The Impact of Biosimilar Competition in Europe. Available from: impact-of-biosimilar-competition-in-europe-iqvia.pdf [Accessed September 2022]